Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man

European Journal of Cancer

Volumn 35, Issue SUPPL. 3, 1999, Pages 29-32

  Mellstedt, H ^a   Fagerberg, J ^a   Osterborg A ^a  

^a Immune and Gene Therapy Laboratory   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN;

CANCER; COLORECTAL CARCINOMA; CONFERENCE PAPER; HUMAN; IMMUNE RESPONSE; MYELOMA; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MICE; NEOPLASMS;

EID: 0032781864     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00089-1     Document Type: Conference Paper

References (17)

1. Tarr P.E., Lin R., Mueller E.A., Kovarik J.M., Guillaume M., Jones T.C. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine. 14:1996;1199-1204.
2. Schlag P., Manasterski M., Gerneth T.et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. Cancer Immunol. Immunother. 35:1992;325-330.
3. Vermorken J.B., Claessen A., Gall H.et al. Randomized phase III trial of active specific immunotherapy (ASI) versus control in patients with Dukes' B2, B3 or C colon cancer. Eur. J. Cancer. 33(Suppl. 8):1997;S162.
4. Hsu F.J., Caspar C.B., Czerwinski D.et al. Tumour-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood. 89:1997;3129-3135.
5. Dranoff G., Jaffee E., Lazenby A.et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:1993;3539-3543.
6. Golumbek P.T., Azhari R., Jaffee E.M.et al. Controlled release, biodegradeable cytokine depots. a new approach in cancer vaccine design Cancer Res. 53:1993;5841-5844.
7. Kwak L.W., Young H.A., Pennington R.W., Weeks S.D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA. 93:1996;10972-10977.
8. Abe J., Wakimoto H., Yoshida Y., Aoyagi M., Hirakawa K., Hamada H. Anti-tumor effect induced by GM-CSF gene modified tumor vaccination. comparison of adenovirus- and retrovirus mediated genetic transduction J. Cancer Res. Clin. Oncol. 121:1995;587-592.
9. Loibner H, Janzek E, Mayor P, Liehl E. Vaccination of rhesus monkeys with an anti-idiotype antibody mimicking Lewis Y: enhancement of the anti-tumor immune response by repeated administrations of recombinant human GM-CSF. Antibody Immunoconjugates, and Radiopharmaceuticals 1995, 8, 64 (abstract).
10. Kantor J., Irvine K., Abrams S., Kaufman H., DiPietro J., Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic, antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. 84:1992;1084-1091.
11. Samanci A., Yi Q., Fagerberg J.et al. Pharmacological administration of GM-CSF was of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant CEA. Cancer Immunol. Immunother. 47:1998;131-142.
12. Shetye J., Christensson B., Rubio C., Rodensjö M., Biberfeld P., Mellstedt H. The tumor associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. Anticancer Res. 9:1989;395-404.
13. Mosolits S., Harmenberg U., Rudén Uet al. Auto-antibodies against the tumor-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol. Immunother. 47:1999;315-320.
14. Riethmüller G., Holz E., Schlimok G.et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer. seven-year outcome of a multicenter randomized trial J. Clin. Oncol. 16:1998;1788-1794.
15. Bergenbrant S., Yi Q., Österborg A.et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br. J. Haematol. 92:1996;840-846.
16. Österborg A., Yi Q., Henriksson L.et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood. 91:1998;2459-2466.
17. Mellstedt H., Österborg A. Active idiotype vaccination in multiple myeloma - GM-CSF may be an important adjuvant cytokine. Pathologie Biologie. 47:1999;211-215.